FGFR2 and non-small cell lung carcinoma: To the best of our knowledge, our study cohort is the first study on the frequencies of KRAS mutation subtypes, driver gene ROS1 rearrangement, drive gene BRAF and ERBB2 mutations, and passenger gene alterations including the FGFR2-TACC2 translocation in Hispanic NSCLC patients.